BIOMARKERS

Molecular Biopsy of Human Tumors

- a resource for Precision Medicine *

654 related articles for article (PubMed ID: 19916729)

  • 1. Retrospective study of total healthcare costs associated with chronic nonvalvular atrial fibrillation and the occurrence of a first transient ischemic attack, stroke or major bleed.
    Boccuzzi SJ; Martin J; Stephenson J; Kreilick C; Fernandes J; Beaulieu J; Hauch O; Kim J
    Curr Med Res Opin; 2009 Dec; 25(12):2853-64. PubMed ID: 19916729
    [TBL] [Abstract][Full Text] [Related]  

  • 2. Anticoagulation for stroke prevention in elderly patients with atrial fibrillation, including those with falls and/or early-stage dementia: a single-center, retrospective, observational study.
    Jacobs LG; Billett HH; Freeman K; Dinglas C; Jumaquio L
    Am J Geriatr Pharmacother; 2009 Jun; 7(3):159-66. PubMed ID: 19616184
    [TBL] [Abstract][Full Text] [Related]  

  • 3. Incidence and economic burden of suspected adverse events and adverse event monitoring during AF therapy.
    Kim MH; Lin J; Hussein M; Battleman D
    Curr Med Res Opin; 2009 Dec; 25(12):3037-47. PubMed ID: 19852699
    [TBL] [Abstract][Full Text] [Related]  

  • 4. Bleeding as an outcome among patients with nonvalvular atrial fibrillation in a large managed care population.
    Deitelzweig SB; Pinsky B; Buysman E; Lacey M; Makenbaeva D; Wiederkehr D; Graham J
    Clin Ther; 2013 Oct; 35(10):1536-45.e1. PubMed ID: 24075151
    [TBL] [Abstract][Full Text] [Related]  

  • 5. Cost of atrial fibrillation in United States managed care organizations.
    Kim MH; Lin J; Hussein M; Kreilick C; Battleman D
    Adv Ther; 2009 Sep; 26(9):847-57. PubMed ID: 19768638
    [TBL] [Abstract][Full Text] [Related]  

  • 6. Warfarin exposure and the risk of thromboembolic and major bleeding events among medicaid patients with atrial fibrillation.
    Boulanger L; Hauch O; Friedman M; Foster T; Dixon D; Wygant G; Menzin J
    Ann Pharmacother; 2006 Jun; 40(6):1024-9. PubMed ID: 16735649
    [TBL] [Abstract][Full Text] [Related]  

  • 7. Healthcare utilization and costs of patients with rosacea in an insured population.
    Romanowicz M; Stephenson JJ; Del Rosso JQ; Lenhart G
    J Drugs Dermatol; 2008 Jan; 7(1):41-9. PubMed ID: 18246697
    [TBL] [Abstract][Full Text] [Related]  

  • 8. One-year follow-up healthcare costs of patients hospitalized for transient ischemic attack or ischemic stroke and discharged with aspirin plus extended-release dipyridamole or clopidogrel.
    Burton TM; Lacey M; Liu F; Yu Y; Monsalvo ML; Lang K; Sander S
    J Med Econ; 2012; 15(6):1217-25. PubMed ID: 22857539
    [TBL] [Abstract][Full Text] [Related]  

  • 9. The costs of warfarin underuse and nonadherence in patients with atrial fibrillation: a commercial insurer perspective.
    Casciano JP; Dotiwala ZJ; Martin BC; Kwong WJ
    J Manag Care Pharm; 2013 May; 19(4):302-16. PubMed ID: 23627576
    [TBL] [Abstract][Full Text] [Related]  

  • 10. Occurrence and characteristics of stroke events in the Atrial Fibrillation Follow-up Investigation of Sinus Rhythm Management (AFFIRM) study.
    Sherman DG; Kim SG; Boop BS; Corley SD; Dimarco JP; Hart RG; Haywood LJ; Hoyte K; Kaufman ES; Kim MH; Nasco E; Waldo AL;
    Arch Intern Med; 2005 May; 165(10):1185-91. PubMed ID: 15911734
    [TBL] [Abstract][Full Text] [Related]  

  • 11. Quality of anticoagulation control and costs of monitoring warfarin therapy among patients with atrial fibrillation in clinic settings: a multi-site managed-care study.
    Menzin J; Boulanger L; Hauch O; Friedman M; Marple CB; Wygant G; Hurley JS; Pezzella S; Kaatz S
    Ann Pharmacother; 2005 Mar; 39(3):446-51. PubMed ID: 15701783
    [TBL] [Abstract][Full Text] [Related]  

  • 12. Predictors of warfarin use among Ohio medicaid patients with new-onset nonvalvular atrial fibrillation.
    Johnston JA; Cluxton RJ; Heaton PC; Guo JJ; Moomaw CJ; Eckman MH
    Arch Intern Med; 2003 Jul; 163(14):1705-10. PubMed ID: 12885686
    [TBL] [Abstract][Full Text] [Related]  

  • 13. The effect and safety of the antithrombotic therapies in patients with atrial fibrillation and CHADS score 1.
    Lee BH; Park JS; Park JH; Park JS; Kwak JJ; Hwang ES; Kim SK; Choi DH; Kim YH; Pak HN
    J Cardiovasc Electrophysiol; 2010 May; 21(5):501-7. PubMed ID: 20021521
    [TBL] [Abstract][Full Text] [Related]  

  • 14. Impact of atrial fibrillation on stroke-related healthcare costs.
    Sussman M; Menzin J; Lin I; Kwong WJ; Munsell M; Friedman M; Selim M
    J Am Heart Assoc; 2013 Nov; 2(6):e000479. PubMed ID: 24275631
    [TBL] [Abstract][Full Text] [Related]  

  • 15. Incremental cost burden to US healthcare payers of atrial fibrillation/atrial flutter patients with additional risk factors.
    Amin AN; Jhaveri M; Lin J
    Adv Ther; 2011 Oct; 28(10):907-26. PubMed ID: 21971681
    [TBL] [Abstract][Full Text] [Related]  

  • 16. The relationship between daily atrial tachyarrhythmia burden from implantable device diagnostics and stroke risk: the TRENDS study.
    Glotzer TV; Daoud EG; Wyse DG; Singer DE; Ezekowitz MD; Hilker C; Miller C; Qi D; Ziegler PD
    Circ Arrhythm Electrophysiol; 2009 Oct; 2(5):474-80. PubMed ID: 19843914
    [TBL] [Abstract][Full Text] [Related]  

  • 17. Anticoagulant prophylaxis against stroke in atrial fibrillation: effectiveness in actual practice.
    Caro JJ; Flegel KM; Orejuela ME; Kelley HE; Speckman JL; Migliaccio-Walle K
    CMAJ; 1999 Sep; 161(5):493-7. PubMed ID: 10497604
    [TBL] [Abstract][Full Text] [Related]  

  • 18. Clinical outcome in Japanese elderly patients with non-valvular atrial fibrillation taking warfarin: a single-center observational study.
    Naganuma M; Shiga T; Sato K; Murasaki K; Hashiguchi M; Mochizuki M; Hagiwara N
    Thromb Res; 2012 Jul; 130(1):21-6. PubMed ID: 22137743
    [TBL] [Abstract][Full Text] [Related]  

  • 19. The CHADS score role in managing anticoagulation after surgical ablation for atrial fibrillation.
    Ad N; Henry L; Schlauch K; Holmes SD; Hunt S
    Ann Thorac Surg; 2010 Oct; 90(4):1257-62. PubMed ID: 20868824
    [TBL] [Abstract][Full Text] [Related]  

  • 20. Ximelagatran compared with warfarin for prevention of thromboembolism in patients with nonvalvular atrial fibrillation: Rationale, objectives, and design of a pair of clinical studies and baseline patient characteristics (SPORTIF III and V).
    Halperin JL;
    Am Heart J; 2003 Sep; 146(3):431-8. PubMed ID: 12947359
    [TBL] [Abstract][Full Text] [Related]  

    [Next]    [New Search]
    of 33.